Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−43.19 USD
−98.30 M USD
0.00 USD
2.32 M
About ZyVersa Therapeutics, Inc.
Sector
CEO
Stephen C. Glover
Headquarters
Weston
Website
Founded
2014
FIGI
BBG01137LPK6
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ZVSA is 0.98 USD — it has decreased by −5.00% in the past 24 hours. Watch ZyVersa Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ZyVersa Therapeutics, Inc. stocks are traded under the ticker ZVSA.
ZVSA stock has fallen by −12.21% compared to the previous week, the month change is a −51.08% fall, over the last year ZyVersa Therapeutics, Inc. has showed a −95.30% decrease.
We've gathered analysts' opinions on ZyVersa Therapeutics, Inc. future price: according to them, ZVSA price has a max estimate of 20.00 USD and a min estimate of 20.00 USD. Watch ZVSA chart and read a more detailed ZyVersa Therapeutics, Inc. stock forecast: see what analysts think of ZyVersa Therapeutics, Inc. and suggest that you do with its stocks.
ZVSA reached its all-time high on Dec 12, 2022 with the price of 8,741.25 USD, and its all-time low was 1.03 USD and was reached on Nov 27, 2024. View more price dynamics on ZVSA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ZVSA stock is 6.76% volatile and has beta coefficient of 0.86. Track ZyVersa Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is ZyVersa Therapeutics, Inc. there?
Today ZyVersa Therapeutics, Inc. has the market capitalization of 2.43 M, it has increased by 5.56% over the last week.
Yes, you can track ZyVersa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ZyVersa Therapeutics, Inc. is going to release the next earnings report on Apr 7, 2025. Keep track of upcoming events with our Earnings Calendar.
ZVSA earnings for the last quarter are −2.43 USD per share, whereas the estimation was −1.60 USD resulting in a −51.88% surprise. The estimated earnings for the next quarter are −2.73 USD per share. See more details about ZyVersa Therapeutics, Inc. earnings.
ZyVersa Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ZVSA net income for the last quarter is −2.40 M USD, while the quarter before that showed −2.76 M USD of net income which accounts for 13.12% change. Track more ZyVersa Therapeutics, Inc. financial stats to get the full picture.
No, ZVSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 3, 2024, the company has 7.00 employees. See our rating of the largest employees — is ZyVersa Therapeutics, Inc. on this list?
Like other stocks, ZVSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ZyVersa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ZyVersa Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ZyVersa Therapeutics, Inc. stock shows the sell signal. See more of ZyVersa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.